Author

M. Oerlemans

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Definition and Prognosis of Mitral Regurgitation in Transthyretin Amyloid Cardiomyopathy: A Multicenter International Cohort Study.

BACKGROUND In transthyretin amyloid cardiomyopathy, mitral regurgitation (MR) severity may be underestimated by conventional (semi-)quantitative echocardiographic criteria due to restrictive low-flow hemodynamics. We sought to define and validate disease-specific MR risk thresholds and compare their prognostic performa...

L. Hauptmann, C. Kronberger, S. Schwarting et al. · Circulation · 0 citations

Open access Aug 2026

Clinical and Metabolic Factors as Predictors of Thirty-Day Readmission in Patients With Acute Decompensated Heart Failure With Reduced Ejection Fraction and Type 2 Diabetes Mellitus

Background Patients with heart failure with reduced ejection fraction (HFrEF) had higher readmission rates than those with normal ejection fractions, and readmission rates were highest in the first 30-days post-admission. About 30% of patients with decompensated heart failure also have type 2 diabetes mellitus (T2DM)....

R. Soerarso, D. Y. Hasanah, E. Yonas et al. · Cardiology Research · 0 citations

Aug 2026

Vitronectin-driven amyloid deposition disrupts mitochondrial homeostasis via integrin-mediated pathway in a humanized mouse model of transthyretin cardiac amyloidosis.

Modulation of integrin signalling represents a potential complementary therapeutic strategy in ATTR-CM beyond TTR suppression and actively drives cardiac amyloid deposition, and disruption of integrin αvβ3/FAK/Akt signalling links amyloid-ECM interactions to mitochondrial dysfunction.

Zeping Qiu, Yingze Fan, J. Qin et al. · European Heart Journal · 1 citation